These patients, with advanced NSCLC, PD-L1 expression ≥ 50%, and no documented EGFR/ALK/ROS1 genomic alterations, were treated with first-line pembrolizumab monotherapy in the real-world setting of US oncology practices. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.